EichorEICHOR
Study identifier: NCT03443999 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Recruiting

S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System

Condition: Coronary Artery Disease  ·  Sponsor: Sahajanand Medical Technologies Limited

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
Where7 locations

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

The primary objective of this registry is to evaluate the safety and efficacy of the Supraflex Family sirolimus-eluting coronary stent system in a 'real-world' patient population requiring stent implantation.

This description comes directly from the study's public registry record.

Talk to the study team

Vibhor Bhatia  ·  +919049528863  ·  vibhor.bhatia@sahmed.com

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: 1. Age ≥ 18 years 2. The patient, or legal representative, has been informed of the nature of the registry and has consented to participate and authorised the collection and release of his/her medical information by signing a Patient Informed Consent Form 3. Treating physician has electively implanted at least one Supraflex Family stent as part of the patient's planned clinical care. 4. The patient is willing and able to cooperate with study procedures and required follow up visits Exclusion Criteria: 1. Women with known pregnancy or who are lactating 2. High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons) 3. Currently participating in another study that has not completed the primary endpoint or that clinically interferes with the current registry requirements 4. Planned surgery within 6-month of PCI unless dual anti-platelet therapy is maintained throughout the peri-surgical period

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (7)

Amphia ZiekenhuisBreda, North Brabant, NetherlandsRecruiting
Catharina ZiekenhuisEindhoven, North Brabant, NetherlandsRecruiting
Tergooi ZiekenhuisBlaricum, North Holland, NetherlandsRecruiting
Medical Center LeeuwardenLeeuwarden, Provincie Friesland, NetherlandsRecruiting
Albert Schweitzer ZiekenhuisDordrecht, South Holland, NetherlandsRecruiting
Maasstad ZiekenhuisRotterdam, South Holland, NetherlandsRecruiting
ZorgSaam HospitalTerneuzen, Zeeuws- Vlaanderen, NetherlandsRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

BredaEindhovenBlaricumLeeuwarden

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →